SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Indoco Remedies - Quaterly Results

01 Feb 2022 Evaluate
A fair growth of 7.78% in the revenue at Rs. 3577.60 millions was reported in the December 2021 quarter as compared to Rs. 3319.40 millions during year-ago period.A comparatively good net profit growth of 31.15% to Rs. 329.70 millions was reported for the quarter ended December 2021 compared to Rs. 251.40 millions of previous same quarter.Operating profit for the quarter ended December 2021 rose to 735.60 millions as compared to 603.30 millions of corresponding quarter ended December 2020.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202112 202012 % Var 202112 202012 % Var 202103 202003 % Var
Sales 3577.60 3319.40 7.78 11308.40 9354.50 20.89 12403.00 11060.00 12.14
Other Income 1.60 3.70 -56.76 20.30 11.50 76.52 31.20 24.30 28.40
PBIDT 735.60 603.30 21.93 2485.60 1701.50 46.08 2266.90 1257.70 80.24
Interest 38.10 60.30 -36.82 111.00 176.70 -37.18 222.20 262.50 -15.35
PBDT 697.50 543.00 28.45 2374.60 1524.80 55.73 2044.70 995.20 105.46
Depreciation 192.20 168.80 13.86 609.10 545.80 11.60 731.20 708.10 3.26
PBT 505.30 374.20 35.03 1765.50 979.00 80.34 1313.50 287.10 357.51
TAX 175.60 122.80 43.00 624.00 304.20 105.13 389.60 44.60 773.54
Deferred Tax 18.40 5.80 217.24 -70.00 -91.50 -23.50 4.90 44.60 -89.01
PAT 329.70 251.40 31.15 1141.50 674.80 69.16 923.90 242.50 280.99
Equity 184.30 184.30 0.00 184.30 184.30 0.00 184.30 184.30 0.00
PBIDTM(%) 20.56 18.17 13.13 21.98 18.19 20.84 18.28 11.37 60.72

Indoco Remedies Share Price

223.00 7.15 (3.31%)
06-May-2026 14:03 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1853.20
Dr. Reddys Lab 1320.00
Cipla 1368.45
Zydus Lifesciences 938.80
Lupin 2444.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×